Study on Orelabrutinib for Patients with Relapsed or Refractory B-Cell Blood Cancers

Inclusion Criteria

• Must be 18 years or older.
• Have a confirmed diagnosis of certain types of B-cell blood cancers, such as follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, or chronic lymphocytic leukemia/small lymphocytic lymphoma.
• Have a life expectancy of at least 4 months.
• Be in good overall health with a performance status score of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have adequate organ function.
• Test negative for active hepatitis B or C infections.

Exclusion Criteria

• Women who are pregnant, breastfeeding, or planning to become pregnant during the study.
• Have previously received certain immune therapies.
• Have known allergies to the study drug or its ingredients.
• Have HIV infection.
• Have received chemotherapy or other investigational treatments within 4 weeks before starting the study drug.
• Have had a stem cell or organ transplant.
• Have received radiation therapy within 6 weeks before starting the study drug.
• Are taking certain blood thinners or medications that affect the liver.
• Have active, uncontrolled infections.
• Have had a recent serious infection requiring IV treatment within 14 days before starting the study drug.
• Have unresolved side effects from previous cancer treatments.
• Have cancer that has spread to the brain or spinal cord.
• Have had major surgery or a significant injury within 28 days before starting the study drug.
• Have another invasive cancer diagnosed in the last 2 years.
• Have significant heart or lung disease.
• Are taking medications that suppress the immune system.